- Home
- SCYX vs VYNE Comparison
SCYX vs VYNE Comparison
Compare SCYX & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCYX
- VYNE
- Stock Information
- Founded
- SCYX 1999
- VYNE 2003
- Country
- SCYX United States
- VYNE United States
- Employees
- SCYX N/A
- VYNE N/A
- Industry
- SCYX Biotechnology: Pharmaceutical Preparations
- VYNE Biotechnology: Pharmaceutical Preparations
- Sector
- SCYX Health Care
- VYNE Health Care
- Exchange
- SCYX Nasdaq
- VYNE Nasdaq
- Market Cap
- SCYX 41.0M
- VYNE 41.9M
- IPO Year
- SCYX 2014
- VYNE 2018
- Fundamental
- Price
- SCYX $1.09
- VYNE $2.32
- Analyst Decision
- SCYX Buy
- VYNE Strong Buy
- Analyst Count
- SCYX 1
- VYNE 2
- Target Price
- SCYX N/A
- VYNE $6.88
- AVG Volume (30 Days)
- SCYX 214.8K
- VYNE 129.4K
- Earning Date
- SCYX 03-27-2025
- VYNE 02-27-2025
- Dividend Yield
- SCYX N/A
- VYNE N/A
- EPS Growth
- SCYX N/A
- VYNE N/A
- EPS
- SCYX N/A
- VYNE N/A
- Revenue
- SCYX $8,566,000.00
- VYNE $493,000.00
- Revenue This Year
- SCYX N/A
- VYNE $28.30
- Revenue Next Year
- SCYX $365.06
- VYNE N/A
- P/E Ratio
- SCYX N/A
- VYNE N/A
- Revenue Growth
- SCYX N/A
- VYNE 39.27
- 52 Week Low
- SCYX $0.90
- VYNE $1.57
- 52 Week High
- SCYX $3.07
- VYNE $4.30
- Technical
- Relative Strength Index (RSI)
- SCYX 46.40
- VYNE 36.13
- Support Level
- SCYX $1.02
- VYNE $2.34
- Resistance Level
- SCYX $1.13
- VYNE $3.00
- Average True Range (ATR)
- SCYX 0.07
- VYNE 0.27
- MACD
- SCYX 0.00
- VYNE -0.08
- Stochastic Oscillator
- SCYX 44.44
- VYNE 8.24
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.